Key Points
- CEO Benjamin Palleiko sold 10,926 shares of KalVista Pharmaceuticals at an average price of $26.78, totaling about $292,598; the filing says the sale was to cover tax withholding tied to vesting equity awards.
- KalVista shares were near their 52-week high, opening at $26.81 and trading up slightly, with the stock’s 52-week range reported as $9.83 to $26.85.
- The company’s latest earnings missed EPS estimates, reporting a quarterly loss of $0.43 per share versus expectations for a $0.38 loss, while revenue came in roughly in line at $39.17 million; analysts currently have a consensus Hold rating and a $30.60 target price.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CFO Brian Piekos sold 1,489 shares of the company's stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the completion of the transaction, the chief financial officer owned 21,661 shares of the company's stock, valued at $580,081.58. This trade represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Brian Piekos also recently made the following trade(s):
- On Friday, April 17th, Brian Piekos sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64.
KalVista Pharmaceuticals Stock Up 0.1%
Shares of NASDAQ:KALV opened at $26.81 on Wednesday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.75 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.83 and a 1-year high of $26.85. The company's fifty day moving average is $21.74 and its two-hundred day moving average is $17.54. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). The company had revenue of $39.17 million for the quarter, compared to analyst estimates of $39.03 million. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.
Analyst Ratings Changes
Several research firms have recently weighed in on KALV. Stifel Nicolaus raised their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, March 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, April 21st. Finally, Leerink Partners downgraded KalVista Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 29th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $30.60.
Get Our Latest Research Report on KALV
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC lifted its holdings in shares of KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 589 shares during the period. The Manufacturers Life Insurance Company increased its position in KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company's stock worth $165,000 after purchasing an additional 818 shares during the period. BNP Paribas Financial Markets increased its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers increased its position in KalVista Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company's stock worth $615,000 after purchasing an additional 1,458 shares during the period. Finally, Royal Bank of Canada grew its position in shares of KalVista Pharmaceuticals by 137.0% during the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company's stock worth $59,000 after buying an additional 1,686 shares during the period.
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
